S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy

DISEASE CHARACTERISTICS: * Histologically confirmed metastatic adenocarcinoma of the prostate * Unresponsive or refractory to hormonal therapy, as defined by at least 1 of the following criteria: * Progression of bidimensionally measurable disease * Progression of evaluable but not measurable disease (bone scan) * At least 2 consecutive rises in PSA and a PSA level of at least 5 ng/mL * No minimum PSA required for measurable disease or non-PSA evaluable disease * Soft tissue disease that has been irradiated within the past 2 months is not considered measurable disease * Prior orchiectomy OR * Medical castration using leuprolide or goserelin * Luteinizing hormone-releasing hormone (LHRH) agonist therapy must continue during study * Prior nonsteroidal antiandrogens (flutamide, ketoconazole, bicalutamide, or nilutamide) allowed if disease progression occurred * No third-space fluid accumulation such as ascites or symptomatic pleural effusion * No brain metastases PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * SWOG 0-3 * Performance status 3 must be due to pain secondary to bone metastases Life expectancy: * Not specified Hematopoietic: * No hypercoagulability Hepatic: * Not specified Renal: * Creatinine no greater than 2.0 mg/dL Cardiovascular: * No history of myocardial infarction * No history of congestive heart failure unless well controlled * No history of cerebrovascular accident or atrial fibrillation * No active thrombophlebitis * Left ventricular ejection fraction (LVEF) at least 50% by Multi Gated Acquisition Scan (MUGA) scan or 2-D echocardiogram Pulmonary: * No history of pulmonary embolus Other: * Recovered from major infections * No other significant active medical illness * No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or stage I or II cancer currently in complete remission PRIOR CONCURRENT THERAPY: Biologic therapy: * At least 4 weeks since prior biologic therapy and recovered * No more than 1 prior biologic therapy regimen * No concurrent biological response modifiers Chemotherapy: * At least 4 weeks since prior chemotherapy and recovered * No more than 1 prior chemotherapy regimen * No prior estramustine, taxanes, anthracyclines, or mitoxantrone * No other concurrent chemotherapy Endocrine therapy: * See Disease Characteristics * At least 4 weeks since prior flutamide or ketoconazole (6 weeks for bicalutamide or nilutamide) * No concurrent corticosteroids or hormonal therapy (except megestrol for hot flashes or continuing LHRH treatment) Radiotherapy: * See Disease Characteristics * Prior samarium Sm 153 lexidronam pentasodium allowed * At least 4 weeks since prior radiotherapy and recovered * No prior radiotherapy to 30% or more of bone marrow * No prior strontium chloride Sr 89 * No concurrent radiotherapy Surgery: * See Disease Characteristics * At least 3 weeks since prior surgery and recovered Other: * At least 4 weeks since prior bisphosphonates * No prior anticoagulation therapy (i.e., warfarin), except aspirin * No concurrent bisphosphonates